Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage

Amylyx (AMLX, Financial) has attracted fresh attention from Citi analyst Geoff Meacham, who has initiated coverage with a Buy rating and set a price target of $12. The analyst highlights the promising pipeline of the company, which includes three assets targeting four indications. These projects are in various stages of development, from early to late stages, and are expected to experience significant advancements through 2025 and into the first half of 2026, offering multiple investment opportunities.

Amylyx is focusing on areas with substantial unmet medical needs, with its ongoing Phase 2 and later phase studies. The studies are built around clear clinical endpoints that increase the likelihood of approval and success. The analyst believes this strategic approach enhances the company’s potential for future growth.

Wall Street Analysts Forecast

Based on the one-year price targets offered by 5 analysts, the average target price for Amylyx Pharmaceuticals Inc (AMLX, Financial) is $10.80 with a high estimate of $16.00 and a low estimate of $8.00. The average target implies an upside of 98.53% from the current price of $5.44. More detailed estimate data can be found on the Amylyx Pharmaceuticals Inc (AMLX) Forecast page.

Based on the consensus recommendation from 7 brokerage firms, Amylyx Pharmaceuticals Inc’s (AMLX, Financial) average brokerage recommendation is currently 1.7, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

AMLX Key Business Developments

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Amylyx Pharmaceuticals Inc (AMLX, Financial) has achieved several meaningful milestones, including dosing the first participant in their pivotal phase 3 lucidity clinical trial for vexatide.
• The company has strengthened its financial position by raising approximately $65.5 million, extending their cash runway through the end of 2026.
• Positive topline data from the phase 2 Helios trial in Wolfram syndrome showed improvement or stabilization across all measured outcomes.
• The company is preparing for a potential commercial launch of vexatide in 2027, pending approval.
• Amylyx Pharmaceuticals Inc (AMLX) has a robust pipeline with multiple clinical trials targeting diseases with high unmet needs, including ALS and progressive supranuclear palsy.

Negative Points

• There are no currently approved treatments for post-bariatric hypoglycemia (PBH), which vexatide aims to address, indicating a high-risk development area.
• The company faces challenges in educating the medical community and patients about PBH and the potential benefits of vexatide.
• The phase 3 lucidity trial for vexatide is still in early stages, with topline data not expected until the first half of 2026.
• Amylyx Pharmaceuticals Inc (AMLX) has experienced a significant decrease in operating expenses, which may indicate reduced activity or cost-cutting measures.
• The company is dealing with residual cash obligations related to the discontinuation of previous products, which could impact financial flexibility.